The repurpose of antibodies that improve severe atopic dermatitis symptoms in patients with and without food allergies may warrant investigation for food allergy management due to the similarities in pathogenesis, including the IL-13 antagonists tralokinumab and lebrikizumab [133]. Here, IL13 is linked to food allergy.